Happy to announce the launch of Blue Ribbon Bio, our new wholly owned Prostate Cancer portfolio company, which will initially house Val201. After carrying out a comprehensive competitor intelligence review we are confident that Val201 is relevant to the future treatment of prostate cancer and the new IP we're intending to file should extend coverage of the assets. We have a detailed development plan which leverages both our in house development expertise through Inaphaea Biolabs and its capability partners as well as external ADME/Tox partners to accelerate development of Val201 2.0 and get it back into the clinic as soon as possible whilst positioning for partnering at the earliest possible opportunity.